BiotechTube
Home/Pipeline/GF-CART03

GF-CART03

Solid tumors

PreclinicalActive

Key Facts

Indication
Solid tumors
Phase
Preclinical
Status
Active
Company
GenomeFrontier Therapeutics

About GenomeFrontier Therapeutics

Taiwan biotech leveraging virus‑free gene‑editing platforms to create CAR‑T/TCR‑T cell therapies for cancer.

View full company profile

Therapeutic Areas

Oncology

Other Solid tumors Drugs

DrugCompanyPhase
APVO603Aptevo TherapeuticsPreclinical
APVO711Aptevo TherapeuticsPreclinical
Platform-derived ImmunotherapyGenCirqPre-clinical
SP-2-225Shuttle PharmaceuticalsPreclinical
SP-1-161Shuttle PharmaceuticalsPreclinical
CAR-T Solid Tumor ProgramCarina BiotechPhase 1/2a
HBM1020Harbour BioMedPhase 1
HBM7022Harbour BioMedPhase 1
HBM9033Harbour BioMedDiscovery
Undisclosed Whole Cell Vaccine Program(s)NeuvogenPre-clinical
SY-5609Syros PharmaceuticalsPhase 1/2
Not Specified (TCR Therapy)T-Cure BiosciencePhase 1